Published Jul 30, 2026, 10:24 PM ET · Updated 3 months ago · 1 source
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
bloomberg
·
Original Report
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.